DISCLOSURE: What to do? 2/22/2016

Similar documents
How Strongly Do You Feel That This Patient Has Glaucoma? % % % % %

My Favourite Cases Anthony B. Litwak, OD, FAAO VA Medical Center Baltimore, MD

Dr. Litwak is on the speaker bureau and advisory panel for Alcon and Zeiss Meditek

Evaluation of ONH Pallor in Glaucoma Patients and Suspects. Leticia Rousso, O.D. Joseph Sowka, O.D

Collaboration in the care of glaucoma patients and glaucoma suspects. Barry Emara MD FRCS(C) Nico Ristorante November 29, 2012

Neuro Ocular Grand Rounds Anthony B. Litwak, OD, FAAO VA Medical Center Baltimore, MD

Visual Field Interpretation Anthony B. Litwak, OD, FAAO VA Medical Center Baltimore, MD

Managing the Patient with POAG

Is this glaucoma? Leo Semes, OD Michael Chaglasian, OD Danica Marrelli, OD. Optometry s Meeting 2015 Seattle, WA

Glaucoma Clinical Update. Barry Emara MD FRCS(C) Giovanni Caboto Club October 3, 2012

7/25/2018 GLAUCOMA: YOU MAKE THE CALL GLAUCOMA: YOU MAKE THE CALL. Please text us your questions! PACHYMETRY

Financial Disclosure. Prostaglandin Analogs (PGs) The Glaucoma Grab Bag: Practical Guidelines for Effective Glaucoma Therapy

Case : The glaucoma consult Case: The Glaucoma Consult Case: The Glaucoma Consult Case : The Glaucoma Consult Case : The weekend call you don t want

10/27/2013. Optic Red Herrings

10/3/2018. Case: 63 year old white female 6/11/2012 visit. Glaucoma Update for the Primary Care OD CHRISTOPHER WOLFE, OD, FAAO, DIPL ABO

DEFINITION: DISCLOSURE: 7/25/2017 OPTIC NERVE GRAND ROUNDS: YOU VE GOT SOME NERVE. Joseph Sowka, OD, FAAO, Diplomate 28 YOF 28 YOF

Reason for Unscheduled Visit

30 Years of Clinical Challenges

53 year old woman attends your practice for routine exam. She has no past medical history or family history of note.

Financial Disclosure. Visual Field Interpretation RELIABILITY VISUAL FIELD INTERPRETATION IN GLAUCOMA METHODS OF DATA PRESENTATION

CHAPTER 13 CLINICAL CASES INTRODUCTION

Mark Dunbar: Disclosure

Visit Type (Check one)

Goals. Glaucoma PARA PEARL TO DO. Vision Loss with Glaucoma

Intro to Glaucoma/2006

Glaucoma Pearls and Grand Rounds Vision Expo East 2016

10/22/2018 MISTAKES YOU CAN T MAKE MISTAKES YOU CAN T MAKE IN NEURO-OPHTHALMIC DISEASE. Joseph Sowka, OD, FAAO, Diplomate MISTAKE NOT TO MAKE 74 YOF

Sequential non-arteritic anterior ischemic optic neuropathy (NAION) Jonathan A. Micieli, MD Valérie Biousse, MD

Neuro-Ocular Grand Rounds

Neuro-Ocular Grand Rounds Anthony B. Litwak,OD, FAAO VA Medical Center Baltimore, Maryland

5/12/2014. Lynn E. Lawrence, CPOT, ABOC, COA

Glaucoma Diagnosis. Definition of Glaucoma. Diagnosing Glaucoma. Vision Institute Annual Fall Conference

Advances in OCT Murray Fingeret, OD

Landmark Glaucoma Studies

Treatments for Open-Angle Glaucoma. A Review of the Research for Adults

Gonioscopy and Slit Lamp Exam for the Glaucoma Suspect. Disclosure GONIOSCOPY: Gonioscopy Why?? What should I look for? GONIOSCOPY

1/25/2019 OCT & OCTA RETINAL IMAGING: HOW TO PREVENT RAGING GLAUCOMA! THE ORIGINAL RAGING GLAUCOMA OCT RETINAL IMAGING OPTIC NERVE HEAD EXAMINATION

Behandlungsstrategien beim Offenwinkelglaukom. F. Bochmann, Augenklinik LUKS

How to Be Efficient and Effective. Disclosure. Topics CASE CM. Case JF 2007 OHTN / POAG? How to Be Efficient and Effective with. with New Technology

Hair Today. Case 1: Meet Ed. Case Background: 10/20/13. Selected Glaucoma Cases COPE: GL. Financial Disclosure

Glaucoma Evaluation. OCT Pearls for Glaucoma. OCT: Retinal Nerve Fiber Layer. Financial Disclosures. OCT: Macula. Case Example

Clinical Discussions in Glaucoma

My Doc told me I needed an eye exam because.. Bruce Onofrey, OD, RPh, FAAO Professor, U. Houston UEI

Jay M. Haynie, O.D.; F.A.A.O. Olympia Tacoma Renton Kennewick Washington

Nate Lighthizer, O.D., F.A.A.O. Assistant Professor, NSUOCO Assistant Dean, Clinical Care Services Director of CE Chief of Specialty Care Clinics

Non-arteritic anterior ischemic optic neuropathy (NAION) with segmental optic disc edema. Jonathan A. Micieli, MD Valérie Biousse, MD

Financial Disclosure. Maximizing OCT in Diagnosis and Management of Glaucoma. Case 1: Dennis, 65yo WM DIAGNOSIS: CASES 1 2 7/29/2016

3/31/2019. Role of IOP. Role of IOP. Role of IOP. Role of IOP. Evaluation of glaucoma has changed Why hasn t treatment?

Snellen VA 2 IOP 3 Ocular Examination * Only dilate if repeat photos required

7/25/2018. You talk about glaucoma in cup-to-disc ratios ASSESSING THE OPTIC DISC: IS PHOTOGRAPHY STILL NECESSARY IN THE OCT ERA?

Long Term Care Formulary RS 14. RESTRICTED STATUS Topical Medical Treatment of Glaucoma 1 of 5

Optic Disc Evaluation: Is the Optic Disc Glaucomatous and Has it Progressed?

Automated Visual Field Analysis for Glaucoma

Disclosures. MT 11/4/2015 Followed for diabetic ret, AMD. Does he have glaucoma too? Glaucoma Case Challenges. George Comer, OD, MBA

Retinal Complications of Obstructive Sleep Apnea A Growing Concern!

Electrodiagnostics Alphabet Soup

OCT : retinal layers. Extraocular muscles. History. Central vs Peripheral vision. History: Temporal course. Optical Coherence Tomography (OCT)

Glaucoma: Diagnostic Modalities

Maximizing Your Diagnostic Technologies: Something Old, New, Borrowed and Blue Greg Caldwell, OD Joseph Sowka, OD Jessica Steen, OD

OCT in the Diagnosis and Follow-up of Glaucoma

Beyond the C/D Ratio: Evaluating a Glaucomatous Optic Nerve. Marcus Gonzales, OD, FAAO Cedar Springs Eye Clinic COPE ID#: GL

Noel de Jesus Atienza, MD, MSc and Joseph Anthony Tumbocon, MD

Unexplained visual loss in seven easy steps

A Curious Case of Bilateral Optic Disc Edema Brittney Dautremont, DO, MPH

Frequently Asked Questions about General Ophthalmology:

Aging & Ophthalmology

Disclosures. How small?

GLAUCOMA SUMMARY BENCHMARKS FOR PREFERRED PRACTICE PATTERN GUIDELINES

Early Detection Of Glaucoma Clinical Clues. Points To Live By. Glaucoma Risk Factors 10/3/2014

NEPTUNE RED BANK BRICK

A Review Of Risk Factors. Early Detection Of Glaucoma Clinical Clues. A risk factor analysis is critical. Points To Live By

Genetics DISCLOSURES. Exfoliation Syndrome 2/28/2017 NEW TOPICS IN GLAUCOMA DIAGNOSIS AND TREATMENT. New Diagnostic Approaches To Glaucoma

ACMO SAMPLE PATIENT 1

You can C-ME after Uveitis

The Optic Nerve Head In Glaucoma. Clinical Pearl #1. Characteristics of Normal Disk 9/26/2017. Initial detectable damage Structure vs function

1/31/2018. Course Objectives. Diagnostic Testing. Optic Nerve Damage ANATOMY AND PHYSIOLOGY OF A GLAUCOMA WORK-UP/TONOMETRY TECHNICIAN: -SDP

CASE 2 IN A SERIES OF 4

OCT Interpretation in Retinal Disease

Keeping Up with the Chaglasian s: Pearls for Glaucoma Cases

STRUCTURE & FUNCTION An Integrated Approach for the Detection and Follow-up of Glaucoma. Module 3a GDx

Glaucoma Surgical Treatments. Murray Fingeret, OD Justin Schweitzer, OD Joe Sowka, OD

4/06/2013. Medication Observation POAG. Proportion. Native American 0.1% 0.4%

1/16/2018. Brett J. Teague, M.D. Big Country Eye Center Abilene, Texas

Role of Initial Preoperative Medical Management in Controlling Post-Operative Anterior Uveitis in Patients of Phacomorphic Glaucoma

Is Posner Schlossman Syndrome Benign?

Marcus Gonzales, OD, FAAO Cedar Springs Eye Clinic

12/2/16. Ways to differentiate:

Targeting Intraocular Pressure in Glaucoma: a Teaching Case Report 1

Morning Report. copyright The University of Colorado. Ashley Laing 09/01/10 Preceptor- Dr. Pantcheva

Page 1. Robert P. Wooldridge, OD, FAAO

DEFINITION: DISCLOSURE: 2/6/2018 CONVERSATIONS IN OPTIC NERVE AND RETINAL VASCULAR DISEASE. Joseph Sowka, OD, FAAO, Diplomate 28 YOF 28 YOF

THE CHRONIC GLAUCOMAS

Is NTG different from POAG?

Neuro-Ophthalmic Masqueraders

Completed Clinical Research Trials Monte Dirks, M.D.

THE OPTIC CHIASM MAY BE DAMAGED BY A VARIETY

THE CHRONIC GLAUCOMAS

9/13/17 DISCLOSURES LATE 50S WM. Honoraria, Consultant or Advisory Board: IS THIS GLAUCOMA?

Grand Rounds Clinical Cases from Alex D. Gibberman, O.D. Harpers Point Eye Associates

Two Pits in a Pod: Using EDI-OCT to evaluate the lamina cribrosa in a patient with openangle glaucoma and multiple optic pits

Transcription:

DISCLOSURE: Dr. Joseph Sowka is a member of the Speakers Bureau for Alcon Laboratories, and Carl Zeiss Meditec. He is on the advisory boards for Alcon, Zeiss, and Allergan. He is a consultant for Alcon. Dr. Sowka has no direct financial interest in any of the diseases, products or instrumentation mentioned in this presentation. Joseph W. Sowka, OD, FAAO, Diplomate What to do? 52 YOWM Treated for presumptive OHTN One parent had POAG (maybe) Initial IOP: 32 mm Hg OD, 30 mm Hg OS Treated PGA IOP: 17 mm Hg Corneas turn out to be thick (610) Should he have been treated? Should we stop? 1

So What Do You Think? OD OS Case: It just isn t clear 24 YOBF CC: Blurred vision OS Happens twice a year since age 7 BVA 20/15 OD, 20/20 OS PERRL (-) RAPD CF: FTFC OD, OS Medical history unremarkable Case: It just isn t clear Conjunctiva clear OU Cornea: steamy edema, KP s A/C deep IOP: 21 mm Hg OD, 70 mm Hg OS 2

So, What are your thoughts? MANAGEMENT This Patient In Office: Pred Forte, Timoptic 0.5%, Alphagan, Trusopt (i gt. each, separated by 5 min) After 30 min: IOP 50 mm Hg; edema completely gone! Now everything is perfect. Can I go now? Repeat regimen: After 30 min: IOP 35 mm Hg Send patient home with Pred Forte Q2H; Alphagan TID F/U 24 Hrs: IOP 10 mm Hg Threshold fields, GDx: Normal OD, OS Points to Ponder Is GCC a truly benign disease? Is GCC a real diagnosis or a variant of uveitic glaucoma? Is GCC an herpetic variant? Bad Prognosis? 78 YOWF Average IOP (1 yr x5); 22 mm OD, 20 mm OS CCT: 517 OD, 527 OS PXE material OU Gonio open OU with moderate pigment 3

Bad Prognosis? PXE glaucoma diagnosed Considerations: Mild field loss Older age Lower initial baseline IOP PXE Can this patient be monitored or should she be treated? Bad Prognosis? Pt answers the question- declines treatment Bad experience with treatment suggested by doctors in past more afraid of treatment than glaucoma Wants to see change or other conclusive proof of need for treatment. However, everything says she will do poorly Peak IOP: 34 mm Hg OD, 37 mm Hg OS Any Final thoughts? All Glaucoma is Not Created Equal 71 YOF Diagnosed POAG OU 2009- treated with Travatan Z will good response (IOP drops to 18 from 28) CCT: 579, 583 Transfers care for convenience Angles open- no evidence of secondary glaucoma All Glaucoma is Not Created Equal 2012: 20/30 OD, 20/400 OS SLT OU x2 Meds: Lumigan, Combigan, Azopt Hx: Used oral CAI 3x/day- hands and feet hurt too much to continue Used pilocarpine- motion sickness IOP- 22 mm OD and 38 mm OS Now What? Now what? 4

All Glaucoma is Not Created Equal Visit 2/14 Not seeing OS since 9/13 20/50 OD, LP OS IOP 36 mm OD, 30 mm OS Now What? Declines surgery again and again All Glaucoma is Not Created Equal N/S until 2/15 Did request med refills throughout, however Using Combigan only- ran out of Azopt and Travatan 20/60 OD, NLP OS IOP 46 mm OD and 72 mm OS Refill all meds Declines surgery again All Glaucoma is Not Created Equal Visit 6/15 Using meds regularly, but was confused when to use Travatan so didn t use it in past week Vision unchanged IOP: 40 mm OD and 53 mm OS New views on surgery Any Final thoughts? Clinical Pearl You can only call a glaucoma patient well controlled in retrospect Some patients progress slowly without treatment and some progress rapidly, even with treatment You don t know who is who until you follow up over time Asymmetric Progression? 76 YOWM- 2008; now 83; US citizen, lives/works Brazil BPH, hypercholesteremia, aortic stenosis Crestor, Flomax, Levitra 20/20 OD, OS Peak IOP 25 mm OD, 20 mm OS CCT 618 OU PERRL (-) RAPD; gonio/sle normal Dx ed POAG OS; OHTN OD vs early POAG Travatan OU Occasionally used DuoTrav 15-16 mm Hg OU 5

2009 2010 2011 2012 2008 2013 3/2015 6

Asymmetric Progression? Treated IOP mid teens Marked field progression OS only Meds changed throughout BP 114/70; 46 BPM Travatan Z/ Simbrinza IOP 12 mm Hg OU Why asymmetric (rapid) marked progression OS? What else to look for? Next step? Now What Do You make of This? 63 YOWF- OHTN OU Treated previously with timolol 0.5% OD only Complained of fatigue with med use Timolol stopped Followed without treatment Q6 mos 6 mos then becomes 18 mos Resident wants to repeat fields and OCT Now What Do You make of This? 2013 2015 Now What? Is Non-Compliance Always Bad? 68 YOF- OHTN Would fields or OCT show what was wrong? 7

Treat or Observe? 2012 CCT: 605; 604 IOP: Low 30s consistently Is Non-Compliance Always Bad? Treatment advocated- pt declines; agrees to close observation 3 mos f/u scheduled- returns 3 years later 2012 2015 Best management now? Any Final thoughts? Help! The Diagnostic Imaging Doesn t Agree with My Diagnosis! 56 YOM- Glaucoma suspect since 2012 8

Is It Only Glaucoma? Is this person really a glaucoma suspect? 53 YOBF- No complaints BVA 20/20 OD, OS Perrl (+) RAPD OS IOP 30 mm Hg OD and 32 mm Hg OS Unilateral sectorial disc pallor with minimal rim damage Color vision testing normal SLE normal OU Anterior chamber angles open gonioscopically. Is this glaucoma or something else like a tumor? Unilateral disc pallor? Glaucoma, something else, or both? Neuroimage or not? 9

Not All Omas are Glaucoma; other things cause cupping Pituitary adenoma Craniopharyngioma Meningioma Glioma Metastatic carcinoma Ischemioma Anterior ischemic optic neuropathy (AION)/ Retinal infarcts Retinaloma Congenitaloma Coincidentaloma Misdiagnosoma Back to the patient Rim minimally notched Disc pallor Unilateral damage No disc hemorrhage/ parapapillary atrophy Age over 50 Arcuate defect- glaucomatous Risk factor- IOP 30s Acuity and color normal But the last doctor said that I had glaucoma 57 YOBF: Diagnosed POAG OU in 2008 based upon disc appearance and abnormal GDx Treated with Travatan z Seen by multiple doctors glaucoma by history Good IOP- CPM Poor compliance can lead to blindness Visual fields- dense superior and inferior arcuate defects Do not use fields for this patient Diagnostic GDx reviewed normal 10

But the last doctor said that I had glaucoma Treated IOP 14 mm Hg OU Fields, discs, imaging normal OU Stop meds IOP rises to 17 mm Hg OD and 18 mm Hg OS New diagnosis: normal Misdiagnosoma 11